Microbot Medical Inc. (NASDAQ: MBOT) announced it has begun the full market release of its LIBERTY Endovascular Robotic System in the United States at the Society of Interventional Radiology Annual Scientific Meeting in Toronto.

The company completed its limited market release phase, during which the LIBERTY system was adopted by multiple healthcare systems including Emory Healthcare and Tampa General Hospital. The system has been used across various procedures including prostate artery embolization, uterine fibroid embolization, and peripheral arterial interventions.

LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. The system is designed to provide precise vascular navigation while reducing radiation exposure and physical strain for medical staff.

To support the full market release, Microbot Medical has expanded its sales team and increased its sales territories from four to eight, with plans to reach 12 territories across the U.S. by the end of 2026.

"We successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across multiple peripheral procedures," said Harel Gadot, Chairman, President and CEO.

The Society of Interventional Radiology represents over 8,000 practicing interventional radiology physicians, trainees, medical students, scientists, and clinical associates. This marks the first time the company has showcased the LIBERTY system at the conference.

Microbot Medical is displaying the system at booth 423 during the conference, which runs from April 11-15. The company is a commercial stage medical device company focused on endovascular procedures through robotic technology.